Trial Profile
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Obinutuzumab (Primary) ; Umbralisib (Primary) ; Bendamustine; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 11 Mar 2023 Status changed from suspended to recruiting.
- 07 Jan 2023 Planned primary completion date changed from 31 Dec 2023 to 30 Jun 2024.
- 07 Jan 2023 Planned End Date changed from 31 Dec 2023 to 30 Jun 2024.